2016年5月26日

Success Stories: NIW Petition Approved for Associate Veterinarian from Nepal in the Field of Immunology


Client’s Testimonial:
“Thanks.”

On January 29th, 2016, we received another EB-2 NIW (National Interest Waiver) approval for an Associate Veterinarian in the Field of Immunology (Approval Notice).

 
 
 
General Field: Immunology
Position at the Time of Case Filing: Associate Veterinarian
Country of Origin: Nepal
Service Center: Texas Service Center (TSC)
State of Residence at the Time of Filing: Texas
Approval Notice Date: January 29th, 2016
Processing Time: 4 months, 7 days

 
Case Summary:
In this EB2-NIW (National Interest Waiver) case, our client is an associate veterinarian from Nepal. He is well known in the field of immunology for researching bovine tuberculosis, investigating the lack of effective treatment for type 1 diabetes in humans, and developing more comprehensive vaccines and treatments that promote improved cell memory and neonatal health. As part of our services, North America Immigration Law Group argued that our client’s research on assessing and combating human and animal immune system diseases contributes to the United States medical research community and ensures progression in the quality of national public health.
Additionally, our carefully presented petition dossier was comprised of the 103 citations that his 17 published papers had collected, and four recommendation letters that our client obtained from specialists in his field. One of these letters stated that “[Client] has already made a major impact on neonatal immunology and other distinct fields in medical science. Given his record, it is inevitable that [Client] will go on advancing his field as well as the greater scientific community for many more years to come.”
It took the USCIS a little over four months to grant their approval. Our legal team recently filed I-485 applications on behalf of our client and his wife, and we wish them all the best in their final step towards permanent residency in the United States.